This report evaluates proton therapy's impact on disease control in pediatric malignancies, indicating reduced late effects.
In children, decades of survivorship magnify the harms of irradiation to normal tissues. Proton therapy (PT) leverages the Bragg peak phenomenon to maintain dose to tumor volumes while reducing dose to surrounding structures. This results in disease control comparable to photons while lowering normal tissue dose and reducing subsequent late effects. The clearest advantages occur when fields are large or when critical organs abut the target volume. Here, we discuss the clinical physics and comparative dosimetry that drive benefit across pediatric indications. We also synthesize PT outcomes for pediatric malignancies and highlight organ-specific late effects where PT reduces the incidence or severity of toxicities. We close with a brief look at the future of particle therapy for pediatric malignancies.
No takes yet. Share an insight, caveat, or question.
Flanagan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: